Lucia Seminario-Vidal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucia Seminario-Vidal has a total of 276 co-authors. Here are the top co-authors by number of shared publications:
Jane Messina
Department of Anatomic Pathology Moffitt Cancer and Research Institute Tampa FLUSA
6 shared publicationsPei-Ling Chen
Cutaneous Oncology Program, H. Lee Moffitt Cancer Center, Tampa, Florida
6 shared publications- Eduardo Rodolfo Lazarowski
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina
5 shared publications Lubomir Sokol
Malignant Hematology Program, H. Lee Moffitt Cancer Center, Tampa, Florida
5 shared publications- Naveed Sami
Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL
5 shared publications - Benjamin Harris Kaffenberger
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
4 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 4227-4231
Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
- 26 June 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 4227-4231
Open AccessLetter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
- Open Access
- 29 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 1427-1431
Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”
- 29 December 2025
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (2) , 1427-1431
Open AccessLetter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”
- 21 May 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (4) , 641-645
A photoaging smartphone application to promote sun safety behaviors among youth in late childhood and adolescence
Background: Ultraviolet (UV)‐exposure behaviors can directly impact an individual's skin cancer risk, with many habits formed during childhood and adolescence. We explored the utility of a photoaging smartphone application to motivate youth to improve sun safety practices.Methods: Participants completed a preintervention survey to gather baseline sun safety perceptions and behaviors. Participants then used a photoaging mobile application to view the projected effects of chronic UV exposure on participants' self‐face image over time, followed by a postintervention survey to assess motivation to engage in future sun safety practices.Results: The study sample included 87 participants (median [interquartile (IQR)] age, 14 [11–16] years). Most participants were White (50.6%) and reported skin type that burns a little and tans easily (42.5%). Preintervention sun exposure behaviors among participants revealed that 33 (37.9%) mostly or always used sunscreen on a sunny day, 48 (55.2%) experienced at least one sunburn over the past year, 26 (30.6%) engaged in outdoor sunbathing at least once during the past year, and zero (0%) used indoor tanning beds. Non‐skin of color (18 [41.9%], p = .02) and older (24 [41.4%], p = .007) participants more often agreed they felt better with a tan. Most participants agreed the intervention increased their motivation to practice sun‐protective behaviors (wear sunscreen, 74 [85.1%]; wear hats, 64 [74.4%]; avoid indoor tanning, 73 [83.9%]; avoid outdoor tanning, 68 [79%]).Conclusion: The findings of this cross‐sectional study suggest that a photoaging smartphone application may serve as a useful tool to promote sun safety behaviors from a young age.
- 21 May 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 41 (4) , 641-645
A photoaging smartphone application to promote sun safety behaviors among youth in late childhood and adolescence
Background: Ultraviolet (UV)‐exposure behaviors can directly impact an individual's skin cancer risk, with many habits formed during childhood and adolescence. We explored the utility of a photoaging smartphone application to motivate youth to improve sun safety practices.Methods: Participants completed a preintervention survey to gather baseline sun safety perceptions and behaviors. Participants then used a photoaging mobile application to view the projected effects of chronic UV exposure on participants' self‐face image over time, followed by a postintervention survey to assess motivation to engage in future sun safety practices.Results: The study sample included 87 participants (median [interquartile (IQR)] age, 14 [11–16] years). Most participants were White (50.6%) and reported skin type that burns a little and tans easily (42.5%). Preintervention sun exposure behaviors among participants revealed that 33 (37.9%) mostly or always used sunscreen on a sunny day, 48 (55.2%) experienced at least one sunburn over the past year, 26 (30.6%) engaged in outdoor sunbathing at least once during the past year, and zero (0%) used indoor tanning beds. Non‐skin of color (18 [41.9%], p = .02) and older (24 [41.4%], p = .007) participants more often agreed they felt better with a tan. Most participants agreed the intervention increased their motivation to practice sun‐protective behaviors (wear sunscreen, 74 [85.1%]; wear hats, 64 [74.4%]; avoid indoor tanning, 73 [83.9%]; avoid outdoor tanning, 68 [79%]).Conclusion: The findings of this cross‐sectional study suggest that a photoaging smartphone application may serve as a useful tool to promote sun safety behaviors from a young age.
- Open Access
Cytokines and Epidermal Lipid Abnormalities in Atopic Dermatitis: A Systematic Review
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and presents a major public health problem worldwide. It is characterized by a recurrent and/or chronic course of inflammatory skin lesions with intense pruritus. Its pathophysiologic features include barrier dysfunction, aberrant immune cell infiltration, and alterations in the microbiome that are associated with genetic and environmental factors. There is a complex crosstalk between these components, which is primarily mediated by cytokines. Epidermal barrier dysfunction is the hallmark of AD and is caused by the disruption of proteins and lipids responsible for establishing the skin barrier. To better define the role of cytokines in stratum corneum lipid abnormalities related to AD, we conducted a systematic review of biomedical literature in PubMed from its inception to 5 September 2023. Consistent with the dominant TH2 skewness seen in AD, type 2 cytokines were featured prominently as possessing a central role in epidermal lipid alterations in AD skin. The cytokines associated with TH1 and TH17 were also identified to affect barrier lipids. Considering the broad cytokine dysregulation observed in AD pathophysiology, understanding the role of each of these in lipid abnormalities and barrier dysfunction will help in developing therapeutics to best achieve barrier homeostasis in AD patients.
Open AccessCytokines and Epidermal Lipid Abnormalities in Atopic Dermatitis: A Systematic Review
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and presents a major public health problem worldwide. It is characterized by a recurrent and/or chronic course of inflammatory skin lesions with intense pruritus. Its pathophysiologic features include barrier dysfunction, aberrant immune cell infiltration, and alterations in the microbiome that are associated with genetic and environmental factors. There is a complex crosstalk between these components, which is primarily mediated by cytokines. Epidermal barrier dysfunction is the hallmark of AD and is caused by the disruption of proteins and lipids responsible for establishing the skin barrier. To better define the role of cytokines in stratum corneum lipid abnormalities related to AD, we conducted a systematic review of biomedical literature in PubMed from its inception to 5 September 2023. Consistent with the dominant TH2 skewness seen in AD, type 2 cytokines were featured prominently as possessing a central role in epidermal lipid alterations in AD skin. The cytokines associated with TH1 and TH17 were also identified to affect barrier lipids. Considering the broad cytokine dysregulation observed in AD pathophysiology, understanding the role of each of these in lipid abnormalities and barrier dysfunction will help in developing therapeutics to best achieve barrier homeostasis in AD patients.
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 159 (2) , 192-197
Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma
Importance: Cutaneous T-cell lymphoma (CTCL) is a group of rare, complex cutaneous malignant neoplasms associated with significant disease burden on patients and the health care system. Currently, the population of patients with CTCL admitted to the hospital remains largely uncharacterized and poorly understood.Objective: To characterize the clinical characteristics, course of hospitalization, and mortality outcomes of an inpatient CTCL cohort.Design, Setting, and Participants: This multicenter retrospective cohort study reviewed medical records for adult patients (age ≥18 years) with a CTCL diagnosis per National Comprehensive Cancer Network guidelines admitted for inpatient hospitalization at 5 US academic medical centers with inpatient dermatology consult services and CTCL clinics between August 2016 and August 2020.Main Outcomes and Measures: Patient demographics, clinical history and findings, hospitalization courses, and mortality outcomes.Results: A total of 79 hospitalized patients with CTCL were identified, including 52 (70.3%) men and 22 (29.7%) women, with a median (IQR) age at hospitalization of 62.9 (27-92) years. The majority of admitted patients with CTCL were White (65 patients [82.3%]), had disease classified as mycosis fungoides (48 patients [61.5%]), and had advanced-stage disease (≥IIB, 70 patients [89.7%]). Most hospitalizations were complicated by infection (45 patients [57.0%]) and required intravenous antibiotic therapy (45 patients [57.0%]). In-hospital mortality occurred in 6 patients (7.6%) and was associated with higher body mass index (36.5 vs 25.3), history of thromboembolic disease (50.0% vs 12.3%), and diagnosis of sepsis on admission (66.7% vs 20.5%). At 1-year postdischarge, 36 patients (49.3%) patients had died, and mortality was associated with history of solid organ cancers (27.8% vs 10.8%), wound care as the reason for dermatology consultation (58.3% vs 24.3%), and presence of large cell transformation (58.3% vs 22.9%).Conclusions and Relevance: The findings of this cohort study improve the understanding of hospitalized patients with CTCL and lend valuable insight into identifying factors associated with both in-hospital and long-term mortality outcomes. This refined understanding of the inpatient CTCL population provides a foundation for larger, more robust studies to identify causal risk factors associated with mortality, development of prognostic scoring systems to estimate the probability of hospital mortality. Overall, the findings may prompt physicians caring for patients with CTCL to implement preventive strategies to diminish hospitalization and improve clinical management across this unique disease spectrum.
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 159 (2) , 192-197
Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma
Importance: Cutaneous T-cell lymphoma (CTCL) is a group of rare, complex cutaneous malignant neoplasms associated with significant disease burden on patients and the health care system. Currently, the population of patients with CTCL admitted to the hospital remains largely uncharacterized and poorly understood.Objective: To characterize the clinical characteristics, course of hospitalization, and mortality outcomes of an inpatient CTCL cohort.Design, Setting, and Participants: This multicenter retrospective cohort study reviewed medical records for adult patients (age ≥18 years) with a CTCL diagnosis per National Comprehensive Cancer Network guidelines admitted for inpatient hospitalization at 5 US academic medical centers with inpatient dermatology consult services and CTCL clinics between August 2016 and August 2020.Main Outcomes and Measures: Patient demographics, clinical history and findings, hospitalization courses, and mortality outcomes.Results: A total of 79 hospitalized patients with CTCL were identified, including 52 (70.3%) men and 22 (29.7%) women, with a median (IQR) age at hospitalization of 62.9 (27-92) years. The majority of admitted patients with CTCL were White (65 patients [82.3%]), had disease classified as mycosis fungoides (48 patients [61.5%]), and had advanced-stage disease (≥IIB, 70 patients [89.7%]). Most hospitalizations were complicated by infection (45 patients [57.0%]) and required intravenous antibiotic therapy (45 patients [57.0%]). In-hospital mortality occurred in 6 patients (7.6%) and was associated with higher body mass index (36.5 vs 25.3), history of thromboembolic disease (50.0% vs 12.3%), and diagnosis of sepsis on admission (66.7% vs 20.5%). At 1-year postdischarge, 36 patients (49.3%) patients had died, and mortality was associated with history of solid organ cancers (27.8% vs 10.8%), wound care as the reason for dermatology consultation (58.3% vs 24.3%), and presence of large cell transformation (58.3% vs 22.9%).Conclusions and Relevance: The findings of this cohort study improve the understanding of hospitalized patients with CTCL and lend valuable insight into identifying factors associated with both in-hospital and long-term mortality outcomes. This refined understanding of the inpatient CTCL population provides a foundation for larger, more robust studies to identify causal risk factors associated with mortality, development of prognostic scoring systems to estimate the probability of hospital mortality. Overall, the findings may prompt physicians caring for patients with CTCL to implement preventive strategies to diminish hospitalization and improve clinical management across this unique disease spectrum.
- Open Access
- 22 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e34054
Perspectives on and Quality of Life in Skin of Color Patients With Mycosis Fungoides/Sézary Syndrome: A Qualitative Analysis
Background Prior quantitative studies have described the diminished health-related quality of life (HRQoL) faced by the overall mycosis fungoides (MF)/Sézary syndrome (SS) population; yet, little is known about how the disease affects HRQoL in skin of color (SOC) patients. This qualitative study sought to explore the lived experiences of SOC patients with MF/SS and gain deeper insights into the impact the disease has on various facets of HRQoL. Methodology Interviews with SOC patients with MF/SS ≥18 were recruited from a cutaneous lymphoma clinic. A thematic analysis was performed to identify overarching themes. Results Ten patients were invited to participate from July to September 2021. One patient with SS and seven patients with MF (four in the early stage and four in the advanced stage), with a median age of 60.5 years, agreed to participate. Emerging themes included diagnostic and therapeutic delays frequently due to initial misdiagnoses with other skin conditions. Physical and functional burdens significantly hindered participants’ abilities to carry out daily responsibilities and maintain employment, and impacts on physical appearance (e.g., darkened skin) led to increased self-consciousness and lack of social acceptance. Participants regarded family and faith as main sources of support in addition to developing healthy coping strategies, such as self-acceptance and adaptability. All participants reported feeling satisfied with their access to healthcare information and the quality of care received. Conclusions Our findings provide greater insights into how HRQoL is impacted across SOC patients with MF/SS, which can help raise awareness among healthcare providers and assist with creating interdisciplinary healthcare approaches to better support the needs of this population.
- 22 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e34054
Open AccessPerspectives on and Quality of Life in Skin of Color Patients With Mycosis Fungoides/Sézary Syndrome: A Qualitative Analysis
Background Prior quantitative studies have described the diminished health-related quality of life (HRQoL) faced by the overall mycosis fungoides (MF)/Sézary syndrome (SS) population; yet, little is known about how the disease affects HRQoL in skin of color (SOC) patients. This qualitative study sought to explore the lived experiences of SOC patients with MF/SS and gain deeper insights into the impact the disease has on various facets of HRQoL. Methodology Interviews with SOC patients with MF/SS ≥18 were recruited from a cutaneous lymphoma clinic. A thematic analysis was performed to identify overarching themes. Results Ten patients were invited to participate from July to September 2021. One patient with SS and seven patients with MF (four in the early stage and four in the advanced stage), with a median age of 60.5 years, agreed to participate. Emerging themes included diagnostic and therapeutic delays frequently due to initial misdiagnoses with other skin conditions. Physical and functional burdens significantly hindered participants’ abilities to carry out daily responsibilities and maintain employment, and impacts on physical appearance (e.g., darkened skin) led to increased self-consciousness and lack of social acceptance. Participants regarded family and faith as main sources of support in addition to developing healthy coping strategies, such as self-acceptance and adaptability. All participants reported feeling satisfied with their access to healthcare information and the quality of care received. Conclusions Our findings provide greater insights into how HRQoL is impacted across SOC patients with MF/SS, which can help raise awareness among healthcare providers and assist with creating interdisciplinary healthcare approaches to better support the needs of this population.
- 19 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (4) , 566-568
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society
Https://doi.org/10.1093/bjd/ljac137 Dear Editor, Pyoderma gangrenosum (PG) is an ulcerative inflammatory condition that typically affects the lower extremities.1 While this disease can result in significant morbidity and mortality, there is currently no standard for defining PG severity or the clinical features determining advanced disease that necessitate more aggressive management. To address this practice gap, a systematic review of existing measures of severity was performed, followed by a Delphi exercise of clinical experts and patients to reach consensus on the clinical features that are critical for defining PG severity. The consensus outcomes will aid in developing a PG-specific severity tool. Institutional Review Board (IRB) approval was received from the Oregon Health & Science University IRB Office. The data underlying this article will be shared upon reasonable request to the corresponding author. Ovid MEDLINE and the Cochrane Library were searched for all English-language article types from January 2000 to June 2021. The Grading of Recommendation Assessment, Development, and Evaluation system was used to evaluate each article. Experts received a summary of the literature review (with level of evidence) before evaluating levels of appropriateness. Three rounds of consensus-building exercises exploring 32 clinical features were administered to PG experts within the Medical Dermatology Society (MDS). We define an expert as a dermatologist who has cared for ≥ 20 patients with PG, similar to parameters used for other rare dermatological diseases (median of 40 patients with PG cared for at the time of study).2 Of the 27 invited experts, 23 completed round 1, followed by 21 and 20 in rounds 2 and 3, respectively. Features that remained uncertain continued onto subsequent rounds of voting. Following round 1, 18 of 20 invited patients with PG (diagnosed with PARACELSUS score3 > 10 from the Pyoderma Gangrenosum Study registry at Oregon Health & Science University)4 rated the importance of subjective clinical features that achieved consensus among experts to determine their validity. These data were relayed to experts in round 2. The RAND/University of California Los Angeles appropriateness method was used to evaluate each clinical feature using a rating scale (1–9) and a level of disagreement measured by a disagreement index (DI). A median appropriateness value of 6.5 ≤ median ≤ 9.0 and a DI ≤ 1 was considered ‘appropriate’. Responses with one or more missing ratings were excluded from analysis, similarly to other Delphi studies.5
- 19 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (4) , 566-568
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society
Https://doi.org/10.1093/bjd/ljac137 Dear Editor, Pyoderma gangrenosum (PG) is an ulcerative inflammatory condition that typically affects the lower extremities.1 While this disease can result in significant morbidity and mortality, there is currently no standard for defining PG severity or the clinical features determining advanced disease that necessitate more aggressive management. To address this practice gap, a systematic review of existing measures of severity was performed, followed by a Delphi exercise of clinical experts and patients to reach consensus on the clinical features that are critical for defining PG severity. The consensus outcomes will aid in developing a PG-specific severity tool. Institutional Review Board (IRB) approval was received from the Oregon Health & Science University IRB Office. The data underlying this article will be shared upon reasonable request to the corresponding author. Ovid MEDLINE and the Cochrane Library were searched for all English-language article types from January 2000 to June 2021. The Grading of Recommendation Assessment, Development, and Evaluation system was used to evaluate each article. Experts received a summary of the literature review (with level of evidence) before evaluating levels of appropriateness. Three rounds of consensus-building exercises exploring 32 clinical features were administered to PG experts within the Medical Dermatology Society (MDS). We define an expert as a dermatologist who has cared for ≥ 20 patients with PG, similar to parameters used for other rare dermatological diseases (median of 40 patients with PG cared for at the time of study).2 Of the 27 invited experts, 23 completed round 1, followed by 21 and 20 in rounds 2 and 3, respectively. Features that remained uncertain continued onto subsequent rounds of voting. Following round 1, 18 of 20 invited patients with PG (diagnosed with PARACELSUS score3 > 10 from the Pyoderma Gangrenosum Study registry at Oregon Health & Science University)4 rated the importance of subjective clinical features that achieved consensus among experts to determine their validity. These data were relayed to experts in round 2. The RAND/University of California Los Angeles appropriateness method was used to evaluate each clinical feature using a rating scale (1–9) and a level of disagreement measured by a disagreement index (DI). A median appropriateness value of 6.5 ≤ median ≤ 9.0 and a DI ≤ 1 was considered ‘appropriate’. Responses with one or more missing ratings were excluded from analysis, similarly to other Delphi studies.5
- Open Access
- 18 April 2022
- Published by Springer Nature in Research Square
Perspectives and quality of life in skin of color patients with mycosis fungoides/Sézary syndrome: a qualitative analysis
Purpose: Prior quantitative studies have described diminished health-related quality-of-life (HRQoL) faced by the mycosis fungoides (MF)/Sézary syndrome (SS) population, yet little is known about how they specifically affect HRQoL in patients with skin of color (SOC). The objective of this qualitative study was to gain insights into the lived experiences of SOC patients with MF/SS and the disease’s impact on various facets of HRQoL. Methods: Interviews with SOC patients with MF/SS ≥18 recruited from a cutaneous lymphoma clinic. A thematic analysis was performed to identify overarching themes.Results: Ten patients were invited to participate during July to September 2021. One SS and seven MF patients [4 early stage, 4 advanced stage] with a median age of 60.5 years agreed to participate. Emerging themes included diagnostic and therapeutic delays frequently due to initial misdiagnoses with other skin conditions. Physical and functional burdens significantly hindered participants’ abilities to carry out daily responsibilities and maintain employment. Impacts on physical appearance (e.g., darkened skin) led to increased self-consciousness and lack of social acceptance. Participants regarded family and faith as main sources of support, in addition to developing healthy coping strategies and personal growth, which included self-acceptance and adaptability. All participants reported feeling satisfied with their access to healthcare information and quality of care received. Conclusion: Our findings provide greater insight into how HRQoL is impacted across SOC patients with MF/SS, which can help raise awareness among healthcare providers and assist with creating interdisciplinary approaches of care to better support the needs of this population.
- 18 April 2022
- Published by Springer Nature in Research Square
Open AccessPerspectives and quality of life in skin of color patients with mycosis fungoides/Sézary syndrome: a qualitative analysis
Purpose: Prior quantitative studies have described diminished health-related quality-of-life (HRQoL) faced by the mycosis fungoides (MF)/Sézary syndrome (SS) population, yet little is known about how they specifically affect HRQoL in patients with skin of color (SOC). The objective of this qualitative study was to gain insights into the lived experiences of SOC patients with MF/SS and the disease’s impact on various facets of HRQoL. Methods: Interviews with SOC patients with MF/SS ≥18 recruited from a cutaneous lymphoma clinic. A thematic analysis was performed to identify overarching themes.Results: Ten patients were invited to participate during July to September 2021. One SS and seven MF patients [4 early stage, 4 advanced stage] with a median age of 60.5 years agreed to participate. Emerging themes included diagnostic and therapeutic delays frequently due to initial misdiagnoses with other skin conditions. Physical and functional burdens significantly hindered participants’ abilities to carry out daily responsibilities and maintain employment. Impacts on physical appearance (e.g., darkened skin) led to increased self-consciousness and lack of social acceptance. Participants regarded family and faith as main sources of support, in addition to developing healthy coping strategies and personal growth, which included self-acceptance and adaptability. All participants reported feeling satisfied with their access to healthcare information and quality of care received. Conclusion: Our findings provide greater insight into how HRQoL is impacted across SOC patients with MF/SS, which can help raise awareness among healthcare providers and assist with creating interdisciplinary approaches of care to better support the needs of this population.
- 1 March 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 991-994
An ulcerating plaque of the lower lip
A middle-aged man presented to a cancer centre with a painful, ulcerating plaque of the lower lip, which had been diagnosed as squamous cell carcinoma. Computed tomography revealed increased focal metabolic activity in the lip, and histology revealed spirochaetes.
- 1 March 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (5) , 991-994
An ulcerating plaque of the lower lip
A middle-aged man presented to a cancer centre with a painful, ulcerating plaque of the lower lip, which had been diagnosed as squamous cell carcinoma. Computed tomography revealed increased focal metabolic activity in the lip, and histology revealed spirochaetes.
- 24 January 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (5) , 1110-1112
A cross-sectional analysis of quality of life in skin of color patients with cutaneous T-cell lymphoma: An exploratory study
- 24 January 2022
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 87 (5) , 1110-1112
A cross-sectional analysis of quality of life in skin of color patients with cutaneous T-cell lymphoma: An exploratory study